Glycopeptide antibiotics: Back to the future

Journal of Antibiotics

Volumn 67, Issue 9, 2014, Pages 631-644

  Butler, Mark S ^a   Hansford, Karl A ^a   Blaskovich, Mark A T ^a   Halai, Reena ^a   Cooper, Matthew A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; GLYCOPEPTIDE; ORITAVANCIN; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; TELAVANCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG USE; EFFECTIVE CONCENTRATION; GRAM POSITIVE INFECTION; HISTAMINE RELEASE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEXT GENERATION SEQUENCING; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG DESIGN; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIOLOGY;

BACTERIA (MICROORGANISMS); POSIBACTERIA;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG APPROVAL; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; GLYCOPEPTIDES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 84921716861     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.111     Document Type: Review

References (205)

1. Butler, M. S. & Cooper, M. A. Antibiotics in the clinical pipeline in 2011. J. Antibiot. 64, 413-425 (2011).
2. Butler, M. S., Blaskovich, M. A. & Cooper, M. A. Antibiotics in the clinical pipeline in 2013. J. Antibiot. 66, 571-591 (2013).
3. Hede, K. Antibiotic resistance: An infectious arms race. Nature 509, S2-S3 (2014).
4. Boucher, H. W. et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).
5. Lewis, K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12, 371-387 (2013).
6. Kirst, H. A. Developing new antibacterials through natural product research. Expert Opin. Drug Discov. 8, 479-493 (2013).
7. Butler, M. S. & Cooper, M. A. Screening strategies to identify new antibiotics. Curr. Drug Targets 13, 373-387 (2012).
8. Shlaes, D. M. & Spellberg, B. Overcoming the challenges to developing new antibiotics. Curr. Opin. Pharmacol. 12, 522-526 (2012).
9. Jones, D. A guiding hand for antibiotics. Nat. Rev. Drug Discov. 10, 161-162 (2011).
10. Anstead, G., Cadena, J. & Javeri, H. in Methicillin-Resistant Staphylococcus Aureus (MRSA) Protocols Vol. 1085 Methods in Molecular Biology (ed. Ji, Y.) 259-309 (Humana Press, New Jersey, 2014).
11. Venugopal, A. A. & Johnson, S. Current state of Clostridium difficile treatment options. Clin. Infect. Dis. 55, S71-S76 (2012).
12. Sensi, P. History of the development of rifampin. Rev. Infect. Dis. 5, S402-S406 (1983).
13. FDA. Accepts Filing of The Medicines Company's New Drug Application for Intravenous Antibiotic Oritavancin with Priority Review (Press Release 19 Feb. 2014) (accessed 15 June 2014).
14. Phillips, I. Withdrawal of growth-promoting antibiotics in Europe and its effects in relation to human health. Int. J. Antimicrob. Agents 30, 101-107 (2007).
15. Lancini, G. C. in Progress in Industrial Microbiology Vol. 27 (eds Bushell, M. E. & Graefe, U.) 283-296 (Elsevier, New York, 1989).
16. Nicolaou, K. C, Boddy, C. N. C, Brase, S. & Winssinger, N. Chemistry, biology, and medicine of the glycopeptide antibiotics. Angew. Chem., Int. Ed. 38, 2096-2152 (1999).
17. Kaneko, I., Fearon, D. T. & Austen, K. F. Inhibition of the alternative pathway of human complement in vitro by a natural microbial product, complestatin. J. Immunol. 124, 1194-1198 (1980).
18. Gouda, H. et al. Stereostructure of (-)-Chloropeptin I, a novel inhibitor of gp120-CD4 binding, via high-temperature molecular dynamics, Monte Carlo conformational searching, and NMR spectroscopy. J. Am. Chem. Soc. 118, 13087-13088 (1996).
19. Pootoolal, J. et al. Assembling the glycopeptide antibiotic scaffold: The biosynthesis of from Streptomyces toyocaensis NRRL15009. Proc. Natl Acad. Sci. USA 99, 8962-8967 (2002).
20. Kobayashi, H. et al. Neuroprotectins A and B, bicyclohexapeptides protecting chick telencephalic neuronal cells from excitotoxicity. I. Fermentation, isolation, physicochemical properties and biological activity. J. Antibiot. 54, 1013-1018 (2001).
21. Kobayashi, H. et al. Neuroprotectins A and B, bicyclohexapeptides protecting chick telencephalic neurons from excitotoxicity. II. Structure determination. J. Antibiot. 54, 1019-1024 (2001).
22. Breazzano, S. P. & Boger, D. L. Synthesis and stereochemical determination of complestatin A and B (neuroprotectin A and B). J. Am. Chem. Soc. 133, 18495-18502 (2011).
23. Yim, G., Thaker, M. N., Koteva, K. & Wright, G. Glycopeptide antibiotic biosynthesis. J. Antibiot. 67, 31-41 (2014).
24. Kahne, D., Leimkuhler, C, Lu, W. & Walsh, C. Glycopeptide and lipoglycopeptide antibiotics. Chem. Rev. 105, 425-448 (2005).
25. Arhin, F. F et al. in Antibiotic Discovery and Development (eds Dougherty, T. J. & Pucci, M. J.) 301-346 (Springer US, New York, 2012).
26. Chmara, H., Ripa, S., Mignini, F & Borowski, E. Bacteriolytic effect of teicoplanin. J. Gen. Microbiol. 137, 913-919 (1991).
27. Allen, N. E., LeTourneau, D. L. & Hobbs, Jr J. N. The role of hydrophobic side chains as determinants of antibacterial activity of semisynthetic glycopeptide antibiotics. J. Antibiot. 50, 677-684 (1997).
28. Allen, N. E. & Nicas, T. I. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26, 511-532 (2003).
29. Higgins, D. L. et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 1127-1134 (2005).
30. Zhanel, G. G. et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70, 859-886 (2010).
31. Belley, A., Harris, R., Beveridge, T., Parr, T. & Moeck, G. Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Antimicrob. Agents Chemother. 53, 800-804 (2009).
32. Lunde, C. S. et al. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor Lipid II. Antimicrob. Agents Chemother. 53, 3375-3383 (2009).
33. Trevino, J. et al. New insights into glycopeptide antibiotic binding to cell wall precursors using SPR and NMR spectroscopy. Chem. Eur. J. 20, 7363-7372 (2014).
34. Beauregard, D. A., Williams, D. H., Gwynn, M. N. & Knowles, D. J. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob. Agents Chemother. 39, 781-785 (1995).
35. Cheng, M. et al. Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin. Org. Biomol. Chem. 12, 2568-2575 (2014).
36. Mackay, J. P. et al. Glycopeptide antibiotic activity and the possible role of dimerization: a model for biological signaling. J. Am. Chem. Soc. 116, 4581-4590 (1994).
37. McCormick, M. H., McGuire, J. M., Pittenger, G. E., Pittenger, R. C. & Stark, W. M. Vancomycin, a new antibiotic. I. Chemical and biologic properties. Antibiot. Annu. 3, 606-611 (1955).
38. Anonymous. Vancomycin. Lancet 269, 85-86 (1957).
39. McGraw, D. J. The Antibiotic Discovery Era (1940-1960): Vancomycin as an Example of the Era (PhD thesis, Oregon State University, 1976).
40. Yao, R. C. & Crandall, L. W. in Glycopeptide Antibiotics Vol. Drugs and the Pharmaceutical Sciences. (ed. Nagarajan, R.) 1-27 (CRC Press, New York, 1994).
41. Levine, D. P. Vancomycin: a history. Clin. Infect. Dis 42(Suppl 1), S5-S12 (2006).
42. Lechevalier, M. P., Prauser, H., Labeda, D. P. & Ruan, J.-S. Two new genera of nocardioform actinomycetes: Amycolata gen. nov. and Amycolatopsis gen. nov. Int. J. Syst. Bacteriol. 36, 29-37 (1986).
43. Griffith, R. S. & Peck, Jr F. B. Vancomycin, a new antibiotic. III. Preliminary clinical and laboratory studies. Antibiot. Annu. 3, 619-622 (1955).
44. Kirby, W. M. M., Perry, D. M. & Bauer, A. W. Treatment of staphylococcal septicemia with vancomycin. New Engl. J. Med. 262, 49-55 (1960).
45. Harris, C. M. & Harris, T. M. Structure of the glycopeptide antibiotic vancomycin. Evidence for an asparagine residue in the peptide. J. Am. Chem. Soc. 104, 4293-4295 (1982).
46. Marshall, F. J. Structure studies on vancomycin. J. Med. Chem. 8, 18-22 (1965).
47. Williams, D. H. & Kalman, J. R. Structural and mode of action studies on the antibiotic vancomycin. Evidence from 270-MHz proton magnetic resonance. J. Am. Chem. Soc. 99, 2768-2774 (1977).
48. Sheldrick, G. M., Jones, P. G., Kennard, O., Williams, D. H. & Smith, G. A. Structure of vancomycin and its complex with acetyl-D-alanyl-D-alanine. Nature 271, 223-225 (1978).
49. Schäfer, M., Schneider, T. R. & Sheldrick, G. M. Crystal structure of vancomycin. Structure 4, 1509-1515 (1996).
50. Evans, D. A. et al. Total syntheses of vancomycin and eremomycin aglycons. Angew. Chem., Int. Ed. 37, 2700-2704 (1998).
51. Nicolaou, K. C. et al. Total synthesis of vancomycin aglycon-Part 3: Final stages. Angew. Chem. Int. Ed. 37, 2717-2719 (1998).
52. Zhang, A. J. & Burgess, K. Total syntheses of vancomycin. Angew. Chem. Int. Ed. 38, 634-636 (1999).
53. Boger, D. L. et al. Diastereoselective total synthesis of the vancomycin aglycon with ordered atropisomer equilibrations. J. Am. Chem. Soc. 121, 3226-3227 (1999).
54. Nicolaou, K. C. et al. Total synthesis of vancomycin aglycon-Part 1: Synthesis of amino acids 4-7 and construction of the AB-COD ring skeleton. Angew. Chem. Int. Ed. 37, 2708-2714 (1998).
55. Nicolaou, K. C. et al. Total synthesis of vancomycin aglycon-Part 2: Synthesis of amino acids 1-3 and construction of the AB-COD-DOE ring skeleton. Angew. Chem. Int. Ed. 37, 2714-2716 (1998).
56. Boger, D. L. et al. Total synthesis of the vancomycin aglycon. J. Am. Chem. Soc. 121, 10004-10011 (1999).
57. Nicolaou, K. C. et al. Total synthesis of vancomycin-Part 1: Design and development of methodology. Chem. Eur. J. 5, 2584-2601 (1999).
58. Nicolaou, K. C. et al. Total synthesis of vancomycin-Part 2: Retrosynthetic analysis, synthesis of amino acid building blocks and strategy evaluations. Chem. Eur. J. 5, 2602-2621 (1999).
59. Nicolaou, K. C. et al. Total synthesis of vancomycin-Part 3: Synthesis of the aglycon. Chem. Eur. J. 5, 2622-2647 (1999).
60. Nicolaou, K. C. et al. Total synthesis of vancomycin-Part 4: Attachment of the sugar moieties and completion of the synthesis. Chem. Eur. J. 5, 2648-2667 (1999).
61. Otto, M. Community-associated MRSA: What makes them special? Int. J. Med. Microbiol. 303, 324-330 (2013).
62. Sowash, M. G. & Uhlemann, A.-C. in Methicillin-Resistant Staphylococcus Aureus (MRSA) Protocols Vol. 1085 Methods in Molecular Biology (ed. Ji, Y.) 25-69 (Humana Press, New Jersey, 2014).
63. CLSI. Methods For Dilution Antimicrobial Susceptibility Tests For Bacteria That Grow Aerobically. Approved standard, 9th ed. CLSI document M7-A9 (CLSI, Wayne, PA, 2011).
64. U. S. Department of Health and Human Services (Centres for Disease Control and Prevention) http://www.cdc.gov/drugresistance/threat-report-2013/ (accessed on 6 June 2014) (2013).
65. McKessar, S. J., Berry, A. M., Bell, J. M., Turnidge, J. D. & Paton, J. C. Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis. Antimicrob. Agents Chemother. 44, 3224-3228 (2000).
66. Depardieu, F., Bonora, M. G., Reynolds, P. E. & Courvalin, P. The vanG glycopeptide resistance operon from Enterococcus faecalis revisited. Mol. Microbiol. 50, 931-948 (2003).
67. Murray, B. E. Vancomycin-resistant enterococcal infections. New Engl. J. Med. 342, 710-721 (2000).
68. Rasmussen, R. V., Fowler, V. G. Jr, Skov, R. & Bruun, N. E. Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA. Future Microbiol. 6, 43-56 (2010).
69. Kim, S. J., Tanaka, K. S. E., Dietrich, E., Rafai Far, A. & Schaefer, J. Locations of the hydrophobic side chains of lipoglycopeptides bound to the peptidoglycan of Staphylococcus aureus. Biochemistry 52, 3405-3414 (2013).
70. Patti, G. J. et al. Vancomycin and oritavancin have different modes of action in Enterococcus faecium. J. Mol. Biol. 392, 1178-1191 (2009).
71. Manson, J. M., Keis, S., Smith, J. M. B. & Cook, G. M. A clonal lineage of VanA-type Enterococcus faecalis predominates in vancomycin-resistant enterococci isolated in New Zealand. Antimicrob. Agents Chemother. 47, 204-210 (2003).
72. Phillips, I. et al. Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. J. Antimicrob. Chemother. 53, 28-52 (2004).
73. D'Costa, V. M. et al. Antibiotic resistance is ancient. Nature 477, 457-461 (2011).
74. Wright, G. D. & Poinar, H. Antibiotic resistance is ancient: implications for drug discovery. Trends Microbiol. 20, 157-159 (2012).
75. Nesme, J. et al. Large-Scale Metagenomic-Based Study of Antibiotic Resistance in the Environment. Curr. Biol. 24, 1096-1100 (2014).
76. Melo-Cristino, J., Resina, C., Manuel, V., Lito, L. & Ramirez, M. First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. Lancet 382, 205 (2013).
77. Rossi, F. et al. Transferable vancomycin resistance in a community-associated MRSA lineage. New Engl. J. Med. 370, 1524-1531 (2014).
78. Hiramatsu, K. in Staphylococci in human disease 2nd Ed., (eds Crossley, K. B. et al.) 193-209 (Wiley-Blackwell, 2009).
79. Howden, B. P., Davies, J. K., Johnson, P. D., Stinear, T. P. & Grayson, M. L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23, 99-139 (2010).
80. Hiramatsu, K. et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350, 1670-1673 (1997).
81. Hiramatsu, K. et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40, 135-136 (1997).
82. Yamakawa, J. et al. Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study. J. Infect. Chemother. 18, 406-409 (2012).
83. Howden, B. P., Peleg, A. Y. & Stinear, T. P. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infect. Genet. Evol. 21, 575-582 (2014).
84. Ike, Y. et al. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J. Clin. Microbiol. 39, 4445-4451 (2001).
85. Matsuo, M. et al. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. Antimicrob. Agents Chemother. 55, 4188-4195 (2011).
86. Cui, L., Neoh, H. M., Shoji, M. & Hiramatsu, K. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 53, 1231-1234 (2009).
87. Cui, L., Lian, J. Q., Neoh, H. M., Reyes, E. & Hiramatsu, K. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 3404-3413 (2005).
88. Neoh, H. M. et al. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob. Agents Chemother. 52, 45-53 (2008).
89. Wootton, M. et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47, 399-403 (2001).
90. Boyle-Vavra, S., Berke, S. K., Lee, J. C. & Daum, R. S. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44, 272-277 (2000).
91. Gardete, S. et al. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog. 8, e1002505 (2012).
92. Plipat, N., Livni, G., Bertram, H. & Thomson, Jr R. B. Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43, 2494-2496 (2005).
93. Belley, A. et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob. Agents Chemother. 54, 5369-5371 (2010).
94. van Hal, S. J. & Paterson, D. L. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55, 405-410 (2011).
95. Zhang, S.-J., Yang, Q., Xu, L., Chang, J. & Sun, X. Synthesis and antibacterial activity against Clostridium difficile of novel demethylvancomycin derivatives. Bioorg. Med. Chem. Lett. 22, 4942-4945 (2012).
96. Boeck, L. D., Mertz, F. P., Wolter, R. K. & Higgens, C. E. N-demethylvancomycin, a novel antibiotic produced by a strain of Nocardia orientalis. Taxonomy and fermentation. J. Antibiot. 37, 446-453 (1984).
97. Vesga, O., Agudelo, M., Salazar, B. E., Rodriguez, C. A. & Zuluaga, A. F. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob. Agents Chemother. 54, 3271-3279 (2010).
98. Rodriguez, C. A., Agudelo, M., Zuluaga, A. F. & Vesga, O. Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model. Antimicrob. Agents Chemother. 56, 243-247 (2012).
99. Tattevin, P. et al. Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits. Antimicrob. Agents Chemother. 57, 1157-1162 (2013).
100. Tenover, F. C. & Moellering, R. C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44, 1208-1215 (2007).
101. Musta, A. C. et al. Vancomycin MIC plus heteroresistance and outcome of methicillinresistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47, 1640-1644 (2009).
102. Dhand, A. & Sakoulas, G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy. F1000 Med. Rep. 4, 4 (2012).
103. Gould, I. M. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int. J. Antimicrob. Agents 31(Suppl 2), 1-9 (2008).
104. van Hal, S. J., Lodise, T. P. & Paterson, D. L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54, 755-771 (2012).
105. van Hal, S. J. et al. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J. Antimicrob. Chemother. 66, 2284-2287 (2011).
106. Fridkin, S. K. et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36, 429-439 (2003).
107. Liu, C. et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52, e18-e55 (2011).
108. Holmes, N. E. et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J. Infect. Dis. 204, 340-347 (2011).
109. Katayama, Y., Murakami-Kuroda, H., Cui, L. & Hiramatsu, K. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem. Antimicrob. Agents Chemother. 53, 3190-3196 (2009).
110. Sakoulas, G., Guram, K., Reyes, K., Nizet, V. & Zervos, M. Human cathelicidin LL-37 resistance and increased daptomycin MIC in USA 600 (ST45) methicillin-resistant Staphylococcus aureus is associated with increased mortality in a hospital setting. J. Clin. Microbiol. 52, 2172-2174 (2014).
111. Matsuo, M., Cui, L., Kim, J. & Hiramatsu, K. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3. Antimicrob. Agents Chemother. 57, 5843-5853 (2013).
112. Mwangi, M. M. et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl Acad. Sci. USA 104, 9451-9456 (2007).
113. Cui, L. et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41, 5-14 (2003).
114. Hanaki, H. et al. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J. Antimicrob. Chemother. 42, 315-320 (1998).
115. Cui, L., Murakami, H., Kuwahara-Arai, K., Hanaki, H. & Hiramatsu, K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44, 2276-2285 (2000).
116. Sieradzki, K. & Tomasz, A. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J. Bacteriol. 185, 7103-7110 (2003).
117. Hanaki, H. et al. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother. 42, 199-209 (1998).
118. Sauvage, E., Kerff, F., Terrak, M., Ayala, J. A. & Charlier, P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol. Rev. 32, 234-258 (2008).
119. Peschel, A., Vuong, C., Otto, M. & Gotz, F. The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob. Agents Chemother. 44, 2845-2847 (2000).
120. Weidenmaier, C. & Peschel, A. Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. Nat. Rev. Microbiol. 6, 276-287 (2008).
121. Falagas, M. E., Makris, G. C., Dimopoulos, G. & Matthaiou, D. K. Heteroresistance: a concern of increasing clinical significance? Clin. Microbiol. Infec. 14, 101-104 (2008).
122. van Hal, S. J. & Fowler, V. G. Jr Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin. Infect. Dis. 56, 1779-1788 (2013).
123. Parenti, F., Beretta, G., Berti, M. & Arioli, V. Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. I. Description of the producer strain, fermentation studies and biological properties. J. Antibiot. 31, 276-283 (1978).
124. Parenti, F. Structure and mechanism of action of teicoplanin. J. Hosp. Infect. 7(Suppl. A), 79-83 (1986).
125. Goldstein, B. P., Rosina, R. & Parenti, F. in Glycopeptide Antibiotics Vol. Drugs and the Pharmaceutical Sciences (ed. Nagarajan, R.) 273-307 (CRC Press, New York, 1994).
126. Barna, J. C. J., Williams, D. H., Stone, D. J. M., Leung, T. W. C. & Doddrell, D. M. Structure elucidation of the teicoplanin antibiotics. J. Am. Chem. Soc. 106, 4895-4902 (1984).
127. Coronelli, C. et al. Teicoplanin, antibiotics from Actinoplanes teichomyceticus nov. sp. V. Aromatic constituents. J. Antibiot. 37, 621-626 (1984).
128. Borghi, A. et al. Isolation and structure determination of two new analogs of teicoplanin, a glycopeptide antibiotic. J. Antibiot. 42, 361-366 (1989).
129. Borghi, A., Edwards, D., Zerilli, L. F. & Lancini, G. C. Factors affecting the normal and branched-chain acyl moieties of teicoplanin components produced by Actinoplanes teichomyceticus. J. Gen. Microbiol. 137, 587-592 (1991).
130. Brink, A. J. et al. Multicomponent antibiotic substances produced by fermentation: Implications for regulatory authorities, critically ill patients and generics. Int. J. Antimicrob. Agents 43, 1-6 (2014).
131. Roberts, J. A. et al. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. Int. J. Antimicrob. Agents 43, 423-430 (2014).
132. Drugs.com website: Targocid, (accessed 27 May 2014).
133. Brogden, R. N. & Peters, D. H. Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47, 823-854 (1994).
134. Pea, F., Brollo, L., Viale, P., Pavan, F. & Furlanut, M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J. Antimicrob. Chemother. 51, 971-975 (2003).
135. Cavalcanti, A. B., Goncalves, A. R., Almeida, C. S., Bugano, D. D. & Silva, E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst. Rev. CD 007022, 1-53 (2010).
136. Périchon, B. & Courvalin, P. in Antibiotic Discovery and Development (eds Dougherty, T. J. & Pucci, M. J.) 515-542 (Springer US, New York, 2012).
137. Kaatz, G. W., Seo, S. M., Dorman, N. J. & Lerner, S. A. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J. Infect. Dis. 162, 103-108 (1990).
138. Shlaes, D. M. & Shlaes, J. H. Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin. Clin. Infect. Dis. 20, 1071-1073 (1995).
139. Mainardi, J. L. et al. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J. Infect. Dis. 171, 1646-1650 (1995).
140. Sieradzki, K. & Tomasz, A. Suppression of glycopeptide resistance in a highly teicoplanin-resistant mutant of Staphylococcus aureus by transposon inactivation of genes involved in cell wall synthesis. Microb. Drug Resist. 4, 159-168 (1998).
141. Mendes, R. E., Sader, H. S., Flamm, R. K., Farrell, D. J. & Jones, R. N. Oritavancin activity against Staphylococcus aureus causing invasive infections in U. S. and European hospitals: a 5-year international surveillance program. Antimicrob. Agents Chemother. 58, 2921-2924 (2014).
142. Philip, J. E., Schenck, J. R. & Hargie, M. P. Ristocetins A and B, two new antibiotics; isolation and properties. Antibiot. Annu 1955-1956, 699-705 (1956).
143. Harris, C. M. & Harris, T. M. Structure of ristocetin A: configurational studies of the peptide. J. Am. Chem. Soc. 104, 363-365 (1982).
144. Nahoum, V., Spector, S. & Loll, P. J. Structure of ristocetin A in complex with a bacterial cell-wall mimetic. Acta Crystallogr. Sect. D: Biol. Crystallogr. 65, 832-838 (2009).
145. Nahoum, V., Spector, S. & Loll, P. Structure of ristocetin A in complex with a bacterial cell-wall mimetic. Corrigendum. Acta. Crystallogr. D. Biol. Crystallogr. 67, 592 (2011).
146. Jawetz, E. Polymyxins, colistin, bacitracin, ristocetin and vancomycin. Pediatr. Clin. North Am. 15, 85-94 (1968).
147. Howard, M. A. & Firkin, B. G. Ristocetin-a new tool in the investigation of platelet aggregation. Thromb. Diath. Haemorrh 26, 362-369 (1971).
148. Jenkins, C. S. P., Meyer, D., Dreyfus, M. D. & Larreu, M. J. Willebrand factor and ristocetin I. Mechanism of ristocetin-induced platelet aggregation. Brit. J. Haematol. 28, 561-578 (1974).
149. Othman, M., Kaur, H. & Emsley, J. Platelet-type von Willebrand disease: new insights into the molecular pathophysiology of a unique platelet defect. Semin. Thromb. Hemost. 39, 663-673 (2013).
150. Kunstmann, M. P., Mitscher, L. A., Porter, J. N., Shay, A. J. & Darken, M. A. LL-AV290, a new antibiotic. I. Fermentation, isolation, and characterization. Antimicrob. Agents Chemother. 8, 242-245 (1968).
151. Redin, G. S. & Dornbush, A. C. LL-AV290, a new antibiotic. II. Antibacterial efficacy in mice and in vitro. Antimicrob. Agents Chemother. 8, 246-248 (1968).
152. Hamill, R. L., Stark, W. M. & DeLong, D. C. (Eli Lilly & Co). Novel antibiotic and a process for the production thereof. US 3, 952, 095 Apr. 20 (1976).
153. McGahren, W. J. et al. Structure of avoparcin components. J. Am. Chem. Soc. 102, 1671-1684 (1980).
154. McGahren, W. J. et al. Components and degradation compounds of the avoparcin complex. J. Antibiot. 36, 1671-1682 (1983).
155. Debono, M. et al. Actaplanin, new glycopeptide antibiotics produced by Actinoplanes missouriensis. The isolation and preliminary chemical characterization of actaplanin. J. Antibiot. 37, 85-95 (1984).
156. Hunt, A. H., Elzey, T. K., Merkel, K. E. & Debono, M. Structures of the actaplanins. J. Org. Chem. 49, 641-645 (1984).
157. Judice, J. K. & Pace, J. L. Semi-synthetic glycopeptide antibacterials. Bioorg. Med. Chem. Lett. 13, 4165-4168 (2003).
158. Leadbetter, M. R. et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot. 57, 326-336 (2004).
159. Corey, G. R., Stryjewski, M. E., Weyenberg, W., Yasothan, U. & Kirkpatrick, P. Telavancin. Nat. Rev. Drug Discov. 8, 929-930 (2009).
160. Lyseng-Williamson, K. & Blick, S. A. Telavancin. Drugs 69, 2607-2620 (2009).
161. Theravance Inc. VIBATIV (TELAVANCIN for Injection) NDA briefing document, 29 Nov. 2012 (accessed 6 June 2014).
162. Kosowska-Shick, K. et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob. Agents Chemother. 53, 4217-4224 (2009).
163. Krause, K. M. et al. In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 74, 429-431 (2012).
164. Pfaller, M. A., Mendes, R. E., Sader, H. S. & Jones, R. N. Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J. Antimicrob. Chemother. 65, 2396-2404 (2010).
165. Durata Therapeutics Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI (Press release 11 December 2012) (accessed 2 June 2014).
166. Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI (press release 25 February 2013) (accessed 2 June 2013).
167. Candiani, G., Abbondi, M., Borgonovi, M., Romanò, G. & Parenti, F. In-vitro and invivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 44, 179-192 (1999).
168. Malabarba, A. & Ciabatti, R. Glycopeptide derivatives. Curr. Med. Chem. 8, 1759-1773 (2001).
169. Malabarba, A. et al. Amides of de-acetylglucosaminyl-deoxy teicoplanin active against highly glycopeptide-resistant enterococci. Synthesis and antibacterial activity. J. Antibiot. 47, 1493-1506 (1994).
170. Borghi, A. et al. Deacylation of the glycopeptide antibiotic A40926 by Actinoplanes teichomyceticus ATCC 31121. J. Antibiot. 49, 607-609 (1996).
171. Malabarba, A. & Goldstein, B. P. Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother. 55, ii15-ii20 (2005).
172. Anderson, V. R. & Keating, G. M. Dalbavancin. Drugs 68, 639-648 (2008).
173. Durata Therapeutics International B. V. Dalbavancin for Injection for Treatment of Acute Bacterial Skin and Skin Structure Infections, NDA 021-883 Briefing Document, 31 Mar. 2014 (accessed 6 June 2014).
174. Jones, R. N., Sader, H. S. & Flamm, R. K. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn. Microbiol. Infect. Dis. 75, 304-307 (2013).
175. Jones, R. N., Sader, H. S., Mendes, R. E. & Flamm, R. K. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn. Microbiol. Infect. Dis. 75, 107-109 (2013).
176. Cooper, R. D. et al. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J. Antibiot. 49, 575-581 (1996).
177. Bouza, E. & Burillo, A. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains. Int. J. Antimicrob. Agents 36, 401-407 (2010).
178. Guskey, M. T. & Tsuji, B. T. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy 30, 80-94 (2010).
179. Allen, N. E. From vancomycin to oritavancin: the discovery and development of a novel lipoglycopeptide antibiotic. Anti-Infect. Agents. Med. Chem. 9, 23-47 (2010).
180. Arhin, F. F., Sarmiento, I., Parr, Jr T. R. & Moeck, G. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J. Antimicrob. Chemother. 64, 868-870 (2009).
181. Thompson, C., Ge, M. & Kahne, D. Synthesis of vancomycin from the aglycon. J. Am. Chem. Soc. 121, 1237-1244 (1999).
182. Nicolaou, K. C. et al. Total synthesis of vancomycin. Angew. Chem. Int. Ed. 38, 240-244 (1999).
183. Boger, D. L. et al. Total synthesis of the teicoplanin aglycon. J. Am. Chem. Soc. 122, 7416-7417 (2000).
184. Evans, D. A., Katz, J. L, Peterson, G. S. & Hintermann, T. Total synthesis of teicoplanin aglycon. J. Am. Chem. Soc. 123, 12411-12413 (2001).
185. Boger, D. L. et al. First and second generation total synthesis of the teicoplanin aglycon. J. Am. Chem. Soc. 123, 1862-1871 (2001).
186. Deng, H. et al. Total synthesis of anti-HIV agent chloropeptin I. J. Am. Chem. Soc 125, 9032-9034 (2003).
187. Crowley, B. M., Mori, Y, McComas, C. C, Tang, D. & Boger, D. L. Total synthesis of the ristocetin aglycon. J. Am. Chem. Soc. 126, 4310-4317 (2004).
188. Rao, A. V. R., Gurjar, M. K., Reddy, K. L. & Rao, A. S. Studies directed toward the synthesis of vancomycin and related cyclic peptides. Chem. Rev. 95, 2135-2167 (1995).
189. Sussmuth, R. D. et al. New Advances in the Biosynthesis of Glycopeptide Antibiotics of the Vancomycin Type from Amycolatopsis mediterranei. Angew. Chem. Int. Ed. 38, 1976-1979 (1999).
190. Weist, S. et al. Fluorobalhimycin-A New Chapter in Glycopeptide Antibiotic Research. Angew. Chem. Int. Ed. 41, 3383-3385 (2002).
191. Evans, D. A. et al. Nonconventional stereochemical issues in the design of the synthesis of the vancomycin antibiotics: challenges imposed by axial and nonplanar chiral elements in the heptapeptide aglycons. Angew. Chem. Int. Ed. 37, 2704-2708 (1998).
192. Boger, D. L. et al. Vancomycin CD and DE macrocyclization and atropisomerism studies. J. Org. Chem. 64, 70-80 (1998).
193. Boger, D. L. et al. Thermal atropisomerism of teicoplanin aglycon derivatives: preparation of the P, P, P and M, P, P atropisomers of the teicoplanin aglycon via selective equilibration of the DE ring system. J. Am. Chem. Soc. 122, 10047-10055 (2000).
194. Xie, J. et al. Total synthesis of [Ψ[C (= S) NH]Tpg4]vancomycin aglycon, [ψ[C (= NH) NH]Tpg4]vancomycin aglycon, and related key compounds: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding. J. Am. Chem. Soc. 134, 1284-1297 (2011).
195. Xie, J., Pierce, J. G., James, R. C, Okano, A. & Boger, D. L. A redesigned vancomycin engineered for dual D-Ala-D-Ala and D-Ala-D-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria. J. Am. Chem. Soc. 133, 13946-13949 (2011).
196. Okano, A., James, R. C, Pierce, J. G., Xie, J. & Boger, D. L. Silver (I)-promoted conversion of thioamides to amidines: divergent synthesis of a key series of vancomycin aglycon residue 4 amidines that clarify binding behavior to model ligands. J. Am. Chem. Soc. 134, 8790-8793 (2012).
197. Malabarba, A., Nicas, T. I. & Thompson, R. C. Structural modifications of glycopeptide antibiotics. Med. Res. Rev. 17, 69-137 (1997).
198. Chang, J. et al. Design, synthesis, and antibacterial activity of demethylvancomycin analogues against drug-resistant bacteria. ChemMedChem 8, 976-984 (2013).
199. Pinter, G. et al. Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study. J. Med. Chem. 52, 6053-6061 (2009).
200. Crane, C. M. et al. Synthesis and evaluation of selected key methyl ether derivatives of vancomycin aglycon. J. Med. Chem. 53, 7229-7235 (2010).
201. Nakama, Y. et al. Discovery of a novel series of semisynthetic vancomycin derivatives effective against vancomycin-resistant bacteria. J. Med. Chem. 53, 2528-2533 (2010).
202. Pinchman, J. R. & Boger, D. L. Probing the role of the vancomycin E-ring aryl chloride: selective divergent synthesis and evaluation of alternatively substituted E-ring analogues. J. Med. Chem. 56, 4116-4124 (2013).
203. Pathak, T. P. & Miller, S. J. Site-selective bromination of vancomycin. J. Am. Chem. Soc. 134, 6120-6123 (2012).
204. Muthyala, R., Rastogi, N., Shin, W. S., Peterson, M. L. & Sham, Y Y Cell permeable vanX inhibitors as vancomycin re-sensitizing agents. Bioorg. Med. Chem. Lett. 24, 2535-2538 (2014).
205. Cooper, M. A. & Williams, D. H. Binding of glycopeptide antibiotics to a model of a vancomycin-resistant bacterium. Chem. Biol. 6, 891-899 (1999).